Shire PLC (LON:SHP) had its price objective cut by equities research analysts at Deutsche Bank AG from GBX 6,000 ($77.49) to GBX 5,700 ($73.61) in a research report issued to clients and investors on Tuesday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Deutsche Bank AG’s target price suggests a potential upside of 44.08% from the stock’s current price.
SHP has been the topic of several other reports. Liberum Capital reaffirmed a “hold” rating and issued a GBX 4,900 ($63.28) price objective on shares of Shire PLC in a research report on Thursday, August 3rd. J P Morgan Chase & Co reaffirmed an “overweight” rating on shares of Shire PLC in a research report on Friday, August 4th. Credit Suisse Group reaffirmed an “outperform” rating and issued a GBX 5,350 ($69.09) price objective on shares of Shire PLC in a research report on Tuesday, August 22nd. Barclays PLC reaffirmed an “overweight” rating and issued a GBX 6,300 ($81.36) price objective on shares of Shire PLC in a research report on Tuesday, June 27th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Shire PLC in a research report on Friday, July 7th. Four research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Shire PLC currently has a consensus rating of “Buy” and an average price target of GBX 5,878.47 ($75.92).
Shire PLC (SHP) opened at 3994.50 on Tuesday. The stock has a 50 day moving average of GBX 3,968.80 and a 200-day moving average of GBX 4,432.95. The firm’s market capitalization is GBX 36.21 billion. Shire PLC has a 1-year low of GBX 3,603.50 and a 1-year high of GBX 5,377.00.
WARNING: This report was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this report can be viewed at https://sportsperspectives.com/2017/09/07/deutsche-bank-ag-lowers-shire-plc-shp-price-target-to-gbx-5700.html.
In other news, insider Flemming Ornskov acquired 8,400 shares of the stock in a transaction dated Tuesday, August 22nd. The shares were bought at an average cost of GBX 3,665 ($47.33) per share, for a total transaction of £307,860 ($397,597.83). Also, insider Dominic Blakemore acquired 152 shares of the stock in a transaction dated Friday, June 30th. The shares were purchased at an average price of GBX 4,255 ($54.95) per share, for a total transaction of £6,467.60 ($8,352.83).
About Shire PLC
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.